What dronedarone does
Dronedarone (brand name Multaq) was developed to take the broad rhythm-stabilizing action of amiodarone and remove the parts of the molecule that cause its long-term side effects. The iodine atoms in amiodarone are what drive most of the thyroid and lung trouble; dronedarone is the same kind of molecule with the iodine taken out. The result is a drug that blocks the same combination of sodium, potassium, calcium, and beta channels — so it works on rhythm in a similar way — but with a much shorter half-life and a cleaner organ-toxicity profile.
The trade-off is real. Dronedarone is less effective than amiodarone at keeping people in normal rhythm. For patients who can take it, that trade-off is worth it; for patients with very stubborn AF, amiodarone may still be the right answer.
Dronedarone is sold in the United States as Multaq (dronedarone) by Sanofi.
Who we prescribe it for
We use dronedarone in a narrow but useful slice of patients:
- Paroxysmal or persistent AF — to reduce the frequency and duration of episodes, and to extend the time spent in normal rhythm after cardioversion.
- Patients who want to avoid amiodarone’s long-term burden and who have reasonable heart function.
We do not use dronedarone in:
- Permanent AF — meaning AF that we are no longer trying to restore to normal rhythm. A large trial (PALLAS) showed harm in this group.
- NYHA Class III or IV heart failure — symptoms with mild activity or at rest. The ANDROMEDA trial showed increased mortality here.
- Patients with reduced ejection fraction and recent decompensation.
- Significant liver disease.
- Combination with strong QT-prolonging drugs.
Before starting dronedarone, we confirm with an echocardiogram that the heart’s pumping function is adequate and that AF is paroxysmal or persistent rather than permanent.
How to take it
Dronedarone is 400 mg twice daily — with breakfast and with dinner. Food matters: absorption is roughly doubled when taken with a meal, so the with-food rule is not optional. Skipping food can reduce effectiveness.
If you miss a dose, take the next dose at the regular time. Do not double up.
Side effects to watch for
Most patients tolerate dronedarone well. Things we hear about:
- GI upset — nausea, diarrhea, abdominal discomfort. This is the most common reason patients stop the drug.
- Mild fatigue or weakness.
- Slow heart rate — from the beta-blocking component.
- Rash or skin sensitivity.
- Modest rise in creatinine that often happens in the first few weeks. This is usually not a true decline in kidney function — dronedarone interferes with how creatinine is secreted — but we still re-check it to make sure.
Serious but uncommon issues we look out for:
- Liver injury — rare but real. We check liver enzymes at baseline, every month for the first six months, and periodically thereafter. New jaundice, dark urine, or right-upper-quadrant pain needs immediate evaluation.
- Worsening heart failure — new shortness of breath, weight gain, leg swelling.
- Lung inflammation — rare, much less common than with amiodarone, but a new cough or breathlessness still gets evaluated.
Drug interactions
Dronedarone is processed by CYP3A4 and is itself an inhibitor of several pathways:
- Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin) — avoid; they raise dronedarone levels significantly.
- Strong CYP3A4 inducers (rifampin, phenytoin, carbamazepine, St. John’s wort) — avoid; they make dronedarone ineffective.
- Digoxin — levels rise meaningfully; we usually reduce the digoxin dose.
- Statins — risk of muscle injury rises with simvastatin and lovastatin; we limit those doses.
- Warfarin — modest INR rise; we check INR more often after starting.
- Dabigatran — levels rise; combination is generally avoided.
- QT-prolonging drugs — combination raises torsades risk.
Grapefruit juice raises dronedarone levels and should be avoided.
How it compares with amiodarone
For patients who fit the criteria, dronedarone is an attractive middle ground:
- Less effective at maintaining rhythm than amiodarone.
- Much shorter half-life (about a day vs. 60 days) — easier to stop and clear.
- No iodine, so the thyroid is left alone.
- Much lower risk of lung, eye, and skin toxicity.
- Liver remains a concern; we still monitor it.
- More restrictive about who can take it (heart failure, permanent AF).
When to call us
Tell us about new shortness of breath, leg swelling, weight gain over a few days, yellowing of the eyes or skin, severe or persistent diarrhea, or any new medication you are about to start.
Manufacturer reference
For official prescribing information, indications, and the latest information on Multaq (dronedarone) from Sanofi, see the manufacturer’s site: multaq.com. (External link — content there is the manufacturer’s and may include promotional material.)